Research programme: cancer therapeutics - Netris PharmaAlternative Names: Anti-SEMA3E monoclonal antibody - Netris Pharma; Anti-semaphorin 3E monoclonal antibody - Netris Pharma; Anti-TrkC monoclonal antibody - Netris Pharma; Anti-tropomyosin receptor kinase C monoclonal antibody - Netris Pharma; SEMA 3E - Netris Pharma
Latest Information Update: 14 Dec 2016
At a glance
- Originator Netris Pharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Semaphorin modulators; TrkC receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Dec 2016 Preclinical trials in Cancer in France (Parenteral) before December 2016